PURPOSE: Wet age-related macular degeneration (AMD), which accounts for most AMD-related vision loss, is characterized by choroidal neovascularization (CNV). The underlying mechanism of CNV is poorly understood, but evidence indicates pathologic recruitment of normal angiogenic signaling pathways such as the VEGF pathway. Recent evidence suggests that the VEGF pathway regulates angiogenesis in concert with Notch signaling. Here, the authors examined the role of Notch signaling in CNV in the backdrop of Notch signaling-mediated regulation of retinal angiogenesis. METHODS: Choroid sclera complexes, after laser-induced CNV, were examined for changes in CNV lesion volume and in proangiogenic and antiangiogenic gene expression after perturbation in Notch signaling. Retinal vessels and angiogenic gene expression in retinal endothelial cells were analyzed in postnatal rats after perturbations in Notch signaling. Notch signaling was activated and inhibited by intravitreal or systemic injection of Jagged1 peptide and gamma secretase inhibitor DAPT, respectively. RESULTS: The authors demonstrated that activation of the canonical Notch pathway reduced the volume of CNV lesions as it attenuated the development of postnatal retinal vasculature. In contrast, inhibition of the Notch pathway exacerbated CNV lesions as it led to the development of hyperdense retinal vasculature. The authors also identified genes associated with proangiogenesis (Vegfr2, Ccr3, and Pdgfb) and antiangiogenesis (Vegfr1 and Unc5b) as targets of Notch signaling-mediated vascular homeostasis, the disruption of which might underlie CNV. CONCLUSIONS: This study suggests that Notch signaling is a key regulator of CNV and thus a molecular target for therapeutic intervention in wet AMD.
PURPOSE: Wet age-related macular degeneration (AMD), which accounts for most AMD-related vision loss, is characterized by choroidal neovascularization (CNV). The underlying mechanism of CNV is poorly understood, but evidence indicates pathologic recruitment of normal angiogenic signaling pathways such as the VEGF pathway. Recent evidence suggests that the VEGF pathway regulates angiogenesis in concert with Notch signaling. Here, the authors examined the role of Notch signaling in CNV in the backdrop of Notch signaling-mediated regulation of retinal angiogenesis. METHODS: Choroid sclera complexes, after laser-induced CNV, were examined for changes in CNV lesion volume and in proangiogenic and antiangiogenic gene expression after perturbation in Notch signaling. Retinal vessels and angiogenic gene expression in retinal endothelial cells were analyzed in postnatal rats after perturbations in Notch signaling. Notch signaling was activated and inhibited by intravitreal or systemic injection of Jagged1 peptide and gamma secretase inhibitor DAPT, respectively. RESULTS: The authors demonstrated that activation of the canonical Notch pathway reduced the volume of CNV lesions as it attenuated the development of postnatal retinal vasculature. In contrast, inhibition of the Notch pathway exacerbated CNV lesions as it led to the development of hyperdense retinal vasculature. The authors also identified genes associated with proangiogenesis (Vegfr2, Ccr3, and Pdgfb) and antiangiogenesis (Vegfr1 and Unc5b) as targets of Notch signaling-mediated vascular homeostasis, the disruption of which might underlie CNV. CONCLUSIONS: This study suggests that Notch signaling is a key regulator of CNV and thus a molecular target for therapeutic intervention in wet AMD.
Authors: Fumi Kinose; Giuseppe Roscilli; Stefania Lamartina; Kenneth D Anderson; Fabio Bonelli; Stanley G Spence; Gennaro Ciliberto; Thomas F Vogt; Daniel J Holder; Carlo Toniatti; Catherine J Thut Journal: Mol Vis Date: 2005-05-27 Impact factor: 2.367
Authors: Matthew T Holderfield; April M Henderson Anderson; Hiroki Kokubo; Michael T Chin; Randy L Johnson; Christopher C W Hughes Journal: Biochem Biophys Res Commun Date: 2006-06-08 Impact factor: 3.575
Authors: Xiaowei Lu; Ferdinand Le Noble; Li Yuan; Quingjan Jiang; Benjamin De Lafarge; Daisuke Sugiyama; Christiane Bréant; Filip Claes; Frederik De Smet; Jean-Léon Thomas; Monica Autiero; Peter Carmeliet; Marc Tessier-Lavigne; Anne Eichmann Journal: Nature Date: 2004-10-27 Impact factor: 49.962
Authors: Atsunobu Takeda; Judit Z Baffi; Mark E Kleinman; Won Gil Cho; Miho Nozaki; Kiyoshi Yamada; Hiroki Kaneko; Romulo J C Albuquerque; Sami Dridi; Kuniharu Saito; Brian J Raisler; Steven J Budd; Pete Geisen; Ariel Munitz; Balamurali K Ambati; Martha G Green; Tatsuro Ishibashi; John D Wright; Alison A Humbles; Craig J Gerard; Yuichiro Ogura; Yuzhen Pan; Justine R Smith; Salvatore Grisanti; M Elizabeth Hartnett; Marc E Rothenberg; Jayakrishna Ambati Journal: Nature Date: 2009-06-14 Impact factor: 49.962
Authors: Joseph F Arboleda-Velasquez; Vincent Primo; Mark Graham; Alexandra James; Jan Manent; Patricia A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 2014-07-11 Impact factor: 4.799
Authors: Xiaoping Qi; Jun Cai; Qing Ruan; Li Liu; Sanford L Boye; Zhijuan Chen; William W Hauswirth; Renee C Ryals; Lynn Shaw; Sergio Caballero; Maria B Grant; Michael E Boulton Journal: Invest Ophthalmol Vis Sci Date: 2012-02-01 Impact factor: 4.799
Authors: Haibo Wang; Erika S Wittchen; Yanchao Jiang; Balamurali Ambati; Hans E Grossniklaus; M Elizabeth Hartnett Journal: Invest Ophthalmol Vis Sci Date: 2011-10-21 Impact factor: 4.799
Authors: Valentina Cipriani; Hin-Tak Leung; Vincent Plagnol; Catey Bunce; Jane C Khan; Humma Shahid; Anthony T Moore; Simon P Harding; Paul N Bishop; Caroline Hayward; Susan Campbell; Ana Maria Armbrecht; Baljean Dhillon; Ian J Deary; Harry Campbell; Malcolm Dunlop; Anna F Dominiczak; Samantha S Mann; Sharon A Jenkins; Andrew R Webster; Alan C Bird; Mark Lathrop; Diana Zelenika; Eric H Souied; José-Alain Sahel; Thierry Léveillard; Angela J Cree; Jane Gibson; Sarah Ennis; Andrew J Lotery; Alan F Wright; David G Clayton; John R W Yates Journal: Hum Mol Genet Date: 2012-06-13 Impact factor: 6.150